- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01841658
Folic Acid Supplementation in Women of Child Bearing Age (FASUPP)
Effect of Obesity and Folic Acid Supplementation on Gene-specific DNA Methylation in Women of Reproductive Age
The objective of this study is to identify genes whose expression is potentially modifiable due to changes in folate intake and help delineate mechanisms accounting for the variability in individual response to folic acid supplementation. The study will be conducted in normal weight and obese women of childbearing age, supplemented for 8 weeks with 800 mcg/day folic acid.
It is hypothesized that (1) a change in folate status, induced by the supplementation, will influence the DNA methylation of specific genes and (2) the DNA methylation response to folic acid supplementation may differ between the normal weight and the obese women of childbearing age.
Study Overview
Detailed Description
This study will be conducted in two phases. An initial screening study will be performed to determine folate status, MTHFR677 genotype and body composition of potential participants of the intervention study. Both folate status and MTHFR677 genotype are known independent predictors of response to folic acid supplementation. Blood samples will be collected, after an overnight fast, for determination of serum folate concentration and for MTHFR677 genotyping. Body composition and 24-hr dietary recalls will also be conducted during the screening visit.
The second phase is an eight week supplementation trial with 800 mcg/day folic acid. Screened individuals determined to have a serum folate < 30 nmol/L (< 50th percentile of NHANES 1999-2004) and of the CC or CT genotype (for MTHFR677) will be eligible for inclusion in the supplementation trial. Participants will be instructed to avoid dietary supplements, fortified ready-to-eat cereals, and other high folate content foods during intervention. Blood samples will be collected, after an overnight fast, at baseline and after 4 and 8 weeks of supplementation for determination of primary (DNA methylation profile) and secondary (nutritional, metabolic and health status biomarkers) outcome measures.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Athens, Georgia, United States, 30602
- University of Georgia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Screening Phase:
- Female 18-40 yr
- Body Mass index 18.5 to 24.9 or > 30 kg/m2
- Intervention Study:
- Serum folate < 30 nmol/L
- MTHFR677CC or MTHFR677CT genotype
Exclusion Criteria:
- Currently pregnant, pregnancy within past 12 months
- Greater than 2 previous pregnancies
- Use of prescription drugs other than oral contraceptives
- Chronic disease (diabetes, hypertension,epilepsy,cancer, kidney disease, CVD)
- Acute illness (pneumonia, urinary tract infection, mononucleosis)
- Use of antibiotics in past 30 days
- Current smoker
- Use of dietary supplements including multivitamins in past 30 days
- Habitual consumption of fortified ready-to-eat cereals
- Significant weight change in past 12 months
- Typical alcohol consumption of 2 or more drinks per day
- INTERVENTION: all above plus serum folate > 30 nmol/L; MTHFR677TT genotype
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Folic Acid Normal Weight
Folic acid, tablet, 800 mcg, daily, eight weeks.
Normal Weight individuals, each will serve as her own control.
|
Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid.
To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff.
Additionally, compliance will be determined by return pill count.
|
Experimental: Folic acid Obese
Folic acid, tablet, 800 mcg, daily, eight weeks.
Obese individuals, each will serve as her own control.
|
Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid.
To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff.
Additionally, compliance will be determined by return pill count.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cell-type-specific DNA methylation
Time Frame: Baseline, 4 weeks and 8 weeks
|
Change in DNA methylation in response to 4 or 8 weeks supplementation with 800 mcg/day of folic acid will be determined in DNA isolated from specific white blood cell types.
Microarray analysis will be used to assess changes in multiple methylation sites within regulatory pathways for folate metabolism and/or development.
Each subject will serve as her own control.
|
Baseline, 4 weeks and 8 weeks
|
Gene-specific DNA methylation
Time Frame: Baseline, 4 weeks and 8 weeks
|
Change in DNA methylation in response to 4 or 8 weeks supplementation with 800 mcg/day of folic acid will be determined in DNA isolated from whole blood .
Microarray analysis will be used to assess changes in multiple methylation sites of specific genes within regulatory pathways for folate metabolism and/or development.
Each subject will serve as her own control.
|
Baseline, 4 weeks and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum folate
Time Frame: Baseline, 4 weeks and 8 weeks
|
Change in serum folate concentrations in response to 4 or 8 weeks supplementation with 800 mcg/day of folic acid will be determined by microbiological assay using Lactobacillus rhamnosus.
Each subject will serve as her own control.
|
Baseline, 4 weeks and 8 weeks
|
Red Blood Cell (RBC) Folate
Time Frame: Baseline, 4 weeks and 8 weeks
|
Change in red blood cell (RBC) folate in response to 4 or 8 weeks supplementation with 800 mcg/day of folic acid will be determined by microbiological assay using Lactobacillus rhamnosus.
|
Baseline, 4 weeks and 8 weeks
|
Body Composition
Time Frame: Baseline and 8 weeks
|
Body composition in terms of fat mass (g), lean mass (g) and % body fat will be determined using the BODPOD instrument and verified by dual-energy X-ray absorptiometry (DXA).
The DXA analysis will also provide an indication of regional fat distribution, and total bone area, bone mineral content and bone density.
|
Baseline and 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lynn B Bailey, PhD, University of Georgia
- Study Director: Dorothy Hausman, PhD, University of Georgia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UGA_FASUPPLEMENT_EPIGEN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Folic acid
-
Universität des SaarlandesCompletedthe Effect of MTHFR C677T on Folate MetabolismGermany
-
Fundacion para la Investigacion Biomedica del Hospital...Completed
-
EndocyteCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Universidade Federal de GoiasFederal University of São Paulo; Ministry of Health, Brazil; Goiania Municipal...Completed
-
Centro Universitario de TonaláNot yet recruitingDrug Abuse | GenotoxicityMexico
-
Università degli Studi dell'InsubriaUniversita di VeronaNot yet recruitingPolycystic Ovary Syndrome
-
Zhao gengliVifor PharmaCompletedIron Deficiency Anemia | Iron DeficiencyChina
-
Wageningen Centre for Food SciencesWageningen UniversityCompletedHealthy | Folate BioavailabilityNetherlands
-
The Hospital for Sick ChildrenDuchesnay Inc.Completed